Fractyl Labs touts data from Revita study

Fractyl Labs said yesterday that a study of its Revita duodenal mucosal resurfacing system reported significant changes in blood sugar in type 2 diabetes patients, similar to those seen with bariatric surgery procedures. Data from the study was presented at the 3rd World Congress on Interventional Therapies for Type 2 Diabetes in London this week, Waltham, Mass.-based Fractyl said. The Revita device is designed to ablate the duodenum (the 1st part of the intestine) in order to alter glucose metabolism. Fractyl calls its approach the “1st procedural therapy to treat type 2 diabetes.” “I appreciate having the opportunity to present our data. Patients in this study had poorly controlled type 2 diabetes, despite medication use. They experienced a significant improvement in HbA1c after this minimally invasive procedure, as well as some weight loss. With this study, we continue to see evidence that the biology of the intestine plays a very important role in type 2 diabetes pathology, and that altering it can meaningfully improve blood sugar control,” Dr. Alan Cherrington of Vanderbilt University said in a press release. The 39-patient proof-of-concept study had primary endpoints of patient safety and reduction in HbA1c after 6 months, and examined patients with “poorly controlled” type 2 diabetes. Patients were treated with either a long-segment or short-segment DMR procedure. The study reported that patients treated with the long-segment tre...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Diabetes Fractyl Source Type: news